Inbok Wee
Primary Care · Lakewood, WANPI 1740900687
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 24.4% of the total. 2025 is the largest year on record at $718, more than ten times the $43 reported in 2022.
Across 75 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- Boehringer Ingelheim$229
- Bayer$121
- Exact Sciences$104
- Lilly USA, LLC$101
- Shield Therapeutics Inc$93
- plus $585 from 14 others
What the payments were for
- Food & beverage$1,631100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $398 |
| Boehringer Ingelheim | 10 | $229 |
| Bayer | 5 | $121 |
| Exact Sciences | 4 | $104 |
| Lilly USA, LLC | 4 | $101 |
| Shield Therapeutics Inc | 4 | $93 |
| Pfizer | 3 | $81 |
| Johnson & Johnson | 3 | $64 |
| GSK | 3 | $62 |
| Novo Nordisk | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $50 |
| Amgen | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Gilead | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| AstraZeneca | 1 | $19 |
How this compares
$1,631 in reported general payments places this provider in the 85th percentile of 94 primary care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 84 | $131,186 |
| JardianceEmpagliflozin | 85 | $90,561 |
| JanuviaSitagliptin Phosphate | 56 | $58,551 |
| VascepaIcosapent Ethyl | 64 | $33,968 |
| ProliaDenosumab | 17 | $29,524 |
| MyrbetriqMirabegron | 32 | $26,287 |
| EliquisApixaban | 22 | $25,193 |
| XareltoRivaroxaban | 20 | $21,448 |
| TradjentaLinagliptin | 15 | $13,138 |
| LinzessLinaclotide | 19 | $12,233 |
| RestasisCyclosporine | 14 | $11,578 |
| FarxigaDapagliflozin Propanediol | 15 | $9,202 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 31 | $6,563 |
| Lidocaine | 61 | $6,501 |
| Omega-3 Acid Ethyl Esters | 51 | $6,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $398 | $154,996117 claims |
| Boehringer IngelheimJardiance, Tradjenta | $229 | $103,699100 claims |
| AmgenProlia | $50 | $29,52417 claims |
| PfizerEliquis | $81 | $25,19322 claims |
| Johnson & JohnsonXarelto | $64 | $21,44820 claims |
| AstraZenecaFarxiga | $19 | $9,20215 claims |
| GSKShingrix, Arnuity Ellipta | $62 | $8,66642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 94 primary care providers in Washington.
Other primary care in Lakewood
- Junghee CheLakewood$20K
- Kyunghee SeoLakewood$871
- Abubakar Abdul-RahmanSeattle$27K
- Margaret StewartMill Creek$14K
- Rhonna LeeSpokane$13K
- Joan ZimmerSpokane$12K
- Kimberly RianoOlympia$8K
- James PittmanSpokane$6K
- Shannon ZawilskiPuyallup$4K
- Laura RaykowskiMontesano$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.